QUOTE AND NEWS
SeekingAlpha  Oct 18  Comment 
By Kevin Quon: On October 16, a questionably malicious article was published here on Seeking Alpha and Yahoo Finance Blogs by TheStreetSweeper, a short only investment group with the intent of profiting off of harsh company critiques. In the...
Motley Fool  Oct 16  Comment 
Solazyme has great potential to be an amazing growth stock, but management needs to do a better job with transparency before investors regain faith in the company. It has a golden opportunity to do so on November 5.
SeekingAlpha  Oct 16  Comment 
By The Street Sweeper: By Sonya Colberg, Senior Investigative Reporter Trouble is blowing the lids off the petri dishes at Solazyme (NASDAQ:SZYM), where the company has fruitlessly toiled for 11 years at turning sugar and algae into profit. The...
StreetInsider.com  Oct 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Solazyme+%28SZYM%29+Adds+Former+DuPont+CFO+as+Director/9901229.html for the full story.
Benzinga  Oct 9  Comment 
me, Inc. (NASDAQ: SZYM) announced today that after successfully completing the build out of a series of important operating capabilities, President David Cole is transitioning from an executive operational role back to the advisory role he...
Motley Fool  Oct 9  Comment 
Is this meaningful or just another movement?
Motley Fool  Oct 7  Comment 
Renewable oil developer Solazyme has been crushed this year by short sellers. Find out why skeptics have piled into Solazyme and whether or not its shares are still worth betting against.
SeekingAlpha  Sep 26  Comment 
By Kevin Quon: On September 24, a seemingly mundane announcement came out of a small private company named Proterro. Proterro announced that it was officially conducting a pilot study in Brazil with Bunge Global Innovation LLC, a wholly owned...
SeekingAlpha  Sep 15  Comment 
By Kevin Quon: Progress appears to be underway for Solazyme (SZYM) when it comes to its new food ingredient brand of AlgaVia. In Solazyme's latest conference call, management announced that the company had signed "an important customer" for...
Motley Fool  Sep 8  Comment 
Investors had grand plans for Solazyme in the beginning of the year. Then reality took over.




 
TOP CONTRIBUTORS


Solazyme (NASDAQ:SZYM) transforms plant-based sugars into petroleum-based products for the chemical industry, fuels, nutrition and skin and personal care products and is scaling up manufacturing capacity in order to better serve these markets. In order to alleviate the manufacturing capacity constraint, Solazyme uses a mixed operational strategy approach including contract manufacturing, and joint ventures. The company's primary revenues are derived from producing oil via an indirect photosynthesis technology. As opposed to common open-pond and photo bio reactor approach, Solazyme uses feeds sugars to proprietary oil-producing micro-algae in a dark fermentation tank to accelerate normal production time. [1]

The rapidly growing demand and depleting supply for oils in today's society has created a need to look to alternatives sources of oil. As a whole, the alternative fuel industry has several advantages including the ability to scale production in order to minimize price variability. The controlled bio reactor production technology also enables company's like Solazyme to produce tailored, high-end fuels for specialized markets.

[2]

The company's initial public offering of stock on the NASDAQ occurred on May 27, 2011. The company offered 11M shares each for $18, which was at the high end of the $15-$17 price range. The offering raised a total of $198M. The lead managers of the IPO were Morgan Stanley (MS) and Goldman Sachs Group (GS).[3]

During the full year 2010, the company reported a total revenue of $38M and incurred a net loss of $16M. This represents a 400% increase in total revenue and a 19% increase in net loss with respect to 2009. [4]

  1. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Prospectus Summary" pg 1-3
  2. SYZM S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg 1-6
  3. Renaissance Capital - IPO Home "Solazyme prices upsized IPO at $18, above the range" 27 May 2011
  4. SYZM S-1/A 2011 PROSPECTUS SUMMARY "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki